These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 26226608

  • 1. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
    Verver EJ, Topsakal V, Kunst HP, Huygen PL, Heller PG, Pujol-Moix N, Savoia A, Benazzo M, Fierro T, Grolman W, Gresele P, Pecci A.
    Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
    [Abstract] [Full Text] [Related]

  • 2. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.
    Pecci A, Klersy C, Gresele P, Lee KJ, De Rocco D, Bozzi V, Russo G, Heller PG, Loffredo G, Ballmaier M, Fabris F, Beggiato E, Kahr WH, Pujol-Moix N, Platokouki H, Van Geet C, Noris P, Yerram P, Hermans C, Gerber B, Economou M, De Groot M, Zieger B, De Candia E, Fraticelli V, Kersseboom R, Piccoli GB, Zimmermann S, Fierro T, Glembotsky AC, Vianello F, Zaninetti C, Nicchia E, Güthner C, Baronci C, Seri M, Knight PJ, Balduini CL, Savoia A.
    Hum Mutat; 2014 Feb; 35(2):236-47. PubMed ID: 24186861
    [Abstract] [Full Text] [Related]

  • 3. Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease.
    Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, Bozzi V, Gresele P, Lethagen S, Fabris F, Dufour C, Granata A, Doubek M, Pecoraro C, Koivisto PA, Heller PG, Iolascon A, Alvisi P, Schwabe D, De Candia E, Rocca B, Russo U, Ramenghi U, Noris P, Seri M, Balduini CL, Savoia A.
    Hum Mutat; 2008 Mar; 29(3):409-17. PubMed ID: 18059020
    [Abstract] [Full Text] [Related]

  • 4. MYH9-Related Thrombocytopenia: Four Novel Variants Affecting the Tail Domain of the Non-Muscle Myosin Heavy Chain IIA Associated with a Mild Clinical Evolution of the Disorder.
    Zaninetti C, De Rocco D, Giangregorio T, Bozzi V, Demeter J, Leoni P, Noris P, Ryhänen S, Barozzi S, Pecci A, Savoia A.
    Hamostaseologie; 2019 Feb; 39(1):87-94. PubMed ID: 29996171
    [Abstract] [Full Text] [Related]

  • 5. Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.
    Sun XH, Wang ZY, Yang HY, Cao LJ, Su J, Yu ZQ, Bai X, Ruan CG.
    Acta Haematol; 2013 Feb; 129(2):106-13. PubMed ID: 23207509
    [Abstract] [Full Text] [Related]

  • 6. Late onset and high-frequency dominant hearing loss in a family with MYH9 disorder.
    Wasano K, Matsunaga T, Ogawa K, Kunishima S.
    Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3547-3552. PubMed ID: 26942920
    [Abstract] [Full Text] [Related]

  • 7. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease.
    Sekine T, Konno M, Sasaki S, Moritani S, Miura T, Wong WS, Nishio H, Nishiguchi T, Ohuchi MY, Tsuchiya S, Matsuyama T, Kanegane H, Ida K, Miura K, Harita Y, Hattori M, Horita S, Igarashi T, Saito H, Kunishima S.
    Kidney Int; 2010 Jul; 78(2):207-14. PubMed ID: 20200500
    [Abstract] [Full Text] [Related]

  • 8. R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17.
    Verver E, Pecci A, De Rocco D, Ryhänen S, Barozzi S, Kunst H, Topsakal V, Savoia A.
    Clin Genet; 2015 Jul; 88(1):85-9. PubMed ID: 24890873
    [Abstract] [Full Text] [Related]

  • 9. Renal manifestations of patients with MYH9-related disorders.
    Han KH, Lee H, Kang HG, Moon KC, Lee JH, Park YS, Ha IS, Ahn HS, Choi Y, Cheong HI.
    Pediatr Nephrol; 2011 Apr; 26(4):549-55. PubMed ID: 21210153
    [Abstract] [Full Text] [Related]

  • 10. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
    Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, Denison JC, Gregory MC, White JG, Barker DF, Greinacher A, Epstein CJ, Glucksman MJ, Martignetti JA.
    Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
    [Abstract] [Full Text] [Related]

  • 11. [Gene analysis and clinical features of MYH9-related disease].
    Luo XJ, Cao K, Liu J, Duan QY, Chen SY, Zhang Y, Huang T, Mao XN, Li CG, Chen YS.
    Zhonghua Er Ke Za Zhi; 2021 Nov 02; 59(11):957-962. PubMed ID: 34711031
    [Abstract] [Full Text] [Related]

  • 12. Genotype-phenotype Correlation of the p.R1165C Mutation in the MYH9 Disorder: Report of a Japanese Pedigree.
    Okano S, Takase M, Iseki K, Toriumi N, Kaneda M, Kunishima S.
    J Pediatr Hematol Oncol; 2015 Aug 02; 37(6):e352-5. PubMed ID: 26056797
    [Abstract] [Full Text] [Related]

  • 13. Characterization of Sensorineural Hearing Loss in Patients With MYH9-Related Disease: A Systematic Review.
    Peddu D, Amin S, Ying YM.
    Otol Neurotol; 2022 Mar 01; 43(3):e298-e308. PubMed ID: 35147601
    [Abstract] [Full Text] [Related]

  • 14. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
    Pecci A, Bozzi V, Panza E, Barozzi S, Gruppi C, Seri M, Balduini CL.
    Thromb Haemost; 2011 Oct 01; 106(4):693-704. PubMed ID: 21833445
    [Abstract] [Full Text] [Related]

  • 15. Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.
    Kunishima S, Yoshinari M, Nishio H, Ida K, Miura T, Matsushita T, Hamaguchi M, Saito H.
    Eur J Haematol; 2007 Mar 01; 78(3):220-6. PubMed ID: 17241369
    [Abstract] [Full Text] [Related]

  • 16. MYH9-related disease: five novel mutations expanding the spectrum of causative mutations and confirming genotype/phenotype correlations.
    De Rocco D, Zieger B, Platokouki H, Heller PG, Pastore A, Bottega R, Noris P, Barozzi S, Glembotsky AC, Pergantou H, Balduini CL, Savoia A, Pecci A.
    Eur J Med Genet; 2013 Jan 01; 56(1):7-12. PubMed ID: 23123319
    [Abstract] [Full Text] [Related]

  • 17. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.
    Arrondel C, Vodovar N, Knebelmann B, Grünfeld JP, Gubler MC, Antignac C, Heidet L.
    J Am Soc Nephrol; 2002 Jan 01; 13(1):65-74. PubMed ID: 11752022
    [Abstract] [Full Text] [Related]

  • 18. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
    Marini M, Bruschi M, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M, Ravazzolo R.
    Int J Mol Med; 2006 May 01; 17(5):729-36. PubMed ID: 16596254
    [Abstract] [Full Text] [Related]

  • 19. Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia.
    Rabbolini DJ, Chun Y, Latimer M, Kunishima S, Fixter K, Valecha B, Tan P, Chew LP, Kile BT, Burt R, Radhakrishnan K, Bird R, Ockelford P, Gabrielli S, Chen Q, Stevenson WS, Ward CM, Morel-Kopp MC.
    Platelets; 2018 Dec 01; 29(8):793-800. PubMed ID: 29090586
    [Abstract] [Full Text] [Related]

  • 20. MYH9-related disorders: report on a patient of Greek origin presenting with macroscopic hematuria and presenile cataract, caused by an R1165C mutation.
    Economou M, Batzios SP, Pecci A, Printza N, Savoia A, Barozzi S, Theodoridou S, Teli A, Psillas G, Zafeiriou DI.
    J Pediatr Hematol Oncol; 2012 Aug 01; 34(6):412-5. PubMed ID: 22627578
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.